Which medication is known to interfere with in vivo 99mTc labeling of red blood cells?

Heparin is known to interfere with the in vivo labeling of red blood cells using technetium-99m (99mTc). This is significant because heparin acts as an anticoagulant, affecting the coagulation process. When used in the setting of preparing for 99mTc labeling, heparin can lead to issues in effective binding and stabilization of the radiopharmaceutical to the red blood cells. This interference can result in decreased efficiency of the labeling process and potential inaccuracies in imaging.

In the context of nuclear medicine, accurate labeling of red blood cells is critical for various diagnostic procedures, including assessing cardiac function or detecting hemorrhage. Heparin's impact on this process highlights the importance of evaluating medications and their potential effects when planning nuclear medicine procedures. In contrast, the other medications do not have a significant impact on the in vivo labeling of red blood cells with 99mTc.